Merck & Company

MRK-N

NYSE:MRK

76.80
1.13 (1.44%)
Merck & Co., Inc., d.b.a. Merck Sharp & Dohme outside the United States and Canada, is an American pharmaceutical company and one of the largest pharmaceutical companies in the world.
More at Wikipedia

Analysis and Opinions about MRK-N

Signal
Opinion
Expert
HOLD
HOLD
July 9, 2020
You'd need to have a Democratic sweep in the upcoming election to have an effect on Wall St. Has a 3.2% yield. Great pipeline of drugs. 8% growth rate. Lagged healthcare the last little while, as most money has gone to Covid treatments. Continues to hold.
Show full opinionHide full opinion
You'd need to have a Democratic sweep in the upcoming election to have an effect on Wall St. Has a 3.2% yield. Great pipeline of drugs. 8% growth rate. Lagged healthcare the last little while, as most money has gone to Covid treatments. Continues to hold.
DON'T BUY
DON'T BUY
June 17, 2020
An Act in the US back in the early 1980's introduced the end of patents with drugs. Patent expiration opened the door for generics. MRK has become the most successful pharma company and has a big patent coming due soon. He would tend to move towards the bio-pharma space instead.
Show full opinionHide full opinion
An Act in the US back in the early 1980's introduced the end of patents with drugs. Patent expiration opened the door for generics. MRK has become the most successful pharma company and has a big patent coming due soon. He would tend to move towards the bio-pharma space instead.
TOP PICK
TOP PICK
May 8, 2020
A Top 100 S&P company, trading in US dollars. His model price is $133.28. A good pullback in price -- good value here. He sees supply chains coming back in health back to US companies. Yield 3.2% (Analysts’ price target is $93.68)
Show full opinionHide full opinion
A Top 100 S&P company, trading in US dollars. His model price is $133.28. A good pullback in price -- good value here. He sees supply chains coming back in health back to US companies. Yield 3.2% (Analysts’ price target is $93.68)
TOP PICK
TOP PICK
February 27, 2020
He doesn't recommend pharma but they are so cheap that he has to. He has a model price of $122.73 or 55% upside. It is a screaming opportunity. (Analysts’ price target is $97.61)
Show full opinionHide full opinion
Merck & Company (MRK-N)
February 27, 2020
He doesn't recommend pharma but they are so cheap that he has to. He has a model price of $122.73 or 55% upside. It is a screaming opportunity. (Analysts’ price target is $97.61)
TOP PICK
TOP PICK
January 30, 2020
Great business. Wide lineup of high margin drugs, robust new pipeline. 23 consecutive quarters of positive earnings surprises. Defensive growth name. 16x earnings, 10-12% growth rate. Yield is 2.82%. (Analysts’ price target is $99.40)
Show full opinionHide full opinion
Merck & Company (MRK-N)
January 30, 2020
Great business. Wide lineup of high margin drugs, robust new pipeline. 23 consecutive quarters of positive earnings surprises. Defensive growth name. 16x earnings, 10-12% growth rate. Yield is 2.82%. (Analysts’ price target is $99.40)
PAST TOP PICK
PAST TOP PICK
January 17, 2020
(A Top Pick Dec 03/18, Up 19%) This company's been on their top picks list since 2016. He spoke to the head of Research when they were brining forward immunotherapy drug Keytruda. The trials are going well over multiple trials. They are also #3 in the animal business too.
Show full opinionHide full opinion
Merck & Company (MRK-N)
January 17, 2020
(A Top Pick Dec 03/18, Up 19%) This company's been on their top picks list since 2016. He spoke to the head of Research when they were brining forward immunotherapy drug Keytruda. The trials are going well over multiple trials. They are also #3 in the animal business too.
TOP PICK
TOP PICK
January 10, 2020
His model price is $126 -- 41% potential upside. Demographics favour it. He can't understand why this sector is still so cheap. Yield 2.72% (Analysts’ price target is $99.24)
Show full opinionHide full opinion
Merck & Company (MRK-N)
January 10, 2020
His model price is $126 -- 41% potential upside. Demographics favour it. He can't understand why this sector is still so cheap. Yield 2.72% (Analysts’ price target is $99.24)
BUY
BUY
November 29, 2019
It's done quite well. New products are coming out. Dividend growth rate was 15% last year which is because of the new product cycle. Revenues were up by 12% which is big for the pharmaceutical sector.
Show full opinionHide full opinion
Merck & Company (MRK-N)
November 29, 2019
It's done quite well. New products are coming out. Dividend growth rate was 15% last year which is because of the new product cycle. Revenues were up by 12% which is big for the pharmaceutical sector.
BUY
BUY
November 1, 2019
Healthcare is a constructive space right now -- defensive, but not too expensive. MRK is a good candidate with a strong return on equity and fair valuation (17 times earnings) and debt is not an issue.
Show full opinionHide full opinion
Merck & Company (MRK-N)
November 1, 2019
Healthcare is a constructive space right now -- defensive, but not too expensive. MRK is a good candidate with a strong return on equity and fair valuation (17 times earnings) and debt is not an issue.
TOP PICK
TOP PICK
October 24, 2019
Has done quite well relative to other healthcare names. Wide line of high marketing drugs, and a good pipeline of new drugs. One of the better names. 22 consecutive quarters of positive earnings. Decent PEG ratio. Yield is 2.66%. (Analysts’ price target is $96.29)
Show full opinionHide full opinion
Merck & Company (MRK-N)
October 24, 2019
Has done quite well relative to other healthcare names. Wide line of high marketing drugs, and a good pipeline of new drugs. One of the better names. 22 consecutive quarters of positive earnings. Decent PEG ratio. Yield is 2.66%. (Analysts’ price target is $96.29)
WAIT
WAIT
October 17, 2019
If he had to pick one pharma, he'd pick Merck. Their pipeline is superior to peers, and well managed. But he wouldn't own the industry at this point in the cycle.
Show full opinionHide full opinion
Merck & Company (MRK-N)
October 17, 2019
If he had to pick one pharma, he'd pick Merck. Their pipeline is superior to peers, and well managed. But he wouldn't own the industry at this point in the cycle.
TOP PICK
TOP PICK
September 11, 2019
Products marketed to over 140 countries. Main drugs in diabetes and oncology. Robust pipeline of new drugs, which will drive revenues over the long term. Not too expensive, with an 11-12% growth rate. Yield is 2.65%. (Analysts’ price target is $96.69)
Show full opinionHide full opinion
Merck & Company (MRK-N)
September 11, 2019
Products marketed to over 140 countries. Main drugs in diabetes and oncology. Robust pipeline of new drugs, which will drive revenues over the long term. Not too expensive, with an 11-12% growth rate. Yield is 2.65%. (Analysts’ price target is $96.69)
BUY
BUY
July 26, 2019

Pfizer vs. Merck He owns both, which both score well in price momentum, high ROE, great balance sheet, pay a sustianble yield and are stable stocks. Merck has slightly better valuation metrics, but both stocks are very similar.

Show full opinionHide full opinion

Pfizer vs. Merck He owns both, which both score well in price momentum, high ROE, great balance sheet, pay a sustianble yield and are stable stocks. Merck has slightly better valuation metrics, but both stocks are very similar.

PAST TOP PICK
PAST TOP PICK
July 17, 2019
(A Top Pick Jul 05/18, Up 37%) It's been his top pick for three years. They continue to execute, like their immunotherapy drug. Trades at only 15x earnings with a good rate of return. The market is focused on their Keytruda therapy which merck is executing well.
Show full opinionHide full opinion
(A Top Pick Jul 05/18, Up 37%) It's been his top pick for three years. They continue to execute, like their immunotherapy drug. Trades at only 15x earnings with a good rate of return. The market is focused on their Keytruda therapy which merck is executing well.
TOP PICK
TOP PICK
July 17, 2019
A diversified drugmaker that generates consistent returns. Patent declines are offset by a deep pipeline of new drugs from acquisitions. Also boast and organic R&D. MRK pays an attractive yield and has a decent balance sheet. Positive developments continue from Keytruda, an immuno-oncology therapy. MRK trades at 15x earnings. (Analysts’ price target is $91.73)
Show full opinionHide full opinion
A diversified drugmaker that generates consistent returns. Patent declines are offset by a deep pipeline of new drugs from acquisitions. Also boast and organic R&D. MRK pays an attractive yield and has a decent balance sheet. Positive developments continue from Keytruda, an immuno-oncology therapy. MRK trades at 15x earnings. (Analysts’ price target is $91.73)
Showing 1 to 15 of 190 entries

Merck & Company(MRK-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 5

Neutral - Hold Signals / Votes : 1

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 7

Stockchase rating for Merck & Company is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Merck & Company(MRK-N) Frequently Asked Questions

What is Merck & Company stock symbol?

Merck & Company is a American stock, trading under the symbol MRK-N on the New York Stock Exchange (MRK). It is usually referred to as NYSE:MRK or MRK-N

Is Merck & Company a buy or a sell?

In the last year, 7 stock analysts published opinions about MRK-N. 5 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is HOLD. Read the latest stock experts' ratings for Merck & Company.

Is Merck & Company a good investment or a top pick?

Merck & Company was recommended as a Top Pick by Stan Wong on 2020-07-09. Read the latest stock experts ratings for Merck & Company.

Why is Merck & Company stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Merck & Company worth watching?

7 stock analysts on Stockchase covered Merck & Company In the last year. It is a trending stock that is worth watching.

What is Merck & Company stock price?

On 2020-07-09, Merck & Company (MRK-N) stock closed at a price of $76.795.